Oncology drugs are medications that are used to treat cancer. These drugs work by targeting and killing cancer cells or slowing down their growth and spread. The oncology drug market in China is a significant and rapidly growing market, driven by the increasing incidence of cancer in the country and the growing demand for effective cancer treatments. 根据最新研究, the oncology drug market in China is poised to grow by USD 41.0 亿期间 2023-2029, 复合年增长率为 12.46% 在预测期内. One of the key drivers of growth in the oncology drug market in China is the increasing incidence of cancer in the country. According to the National Cancer Center of China, the number of new cancer cases in China is expected to reach 4.5 百万 2025. This has led to a growing demand for effective cancer treatments and has created opportunities for pharmaceutical companies to develop and market new oncology drugs. Another factor driving growth in the oncology drug market in China is the increasing government support for cancer research and treatment. The Chinese government has launched several initiatives to improve cancer prevention, 诊断, and treatment, and has increased funding for cancer research and development. 此外, the rise of precision medicine and targeted therapies has led to the development of new oncology drugs that are more effective and have fewer side effects compared to traditional chemotherapy. These drugs are designed to target specific cancer cells or genetic mutations, and are personalized to each patient’s unique cancer profile.

这份行业报告提供了中国市场的市场预测, 其次是类型的详细分析, and product. The China market data on oncology drug can be segmented by type: breast, colorectum, 肝, 肺癌, stomach, thyroid, 其他的. Oncology drug market is further segmented by product: chemotherapy drugs, immunotherapy drugs, targeted drugs. Chemotherapy drugs was the highest contributor to the oncology drug market in China. 向前走, the immunotherapy drugs segment is projected to witness the highest CAGR during the forecast period.

The China oncology drug market is highly competitive. The oncology drug market is dominated by key players, which are AstraZeneca plc., 百时美施贵宝公司, 伊利礼来公司, Jiangsu Chia Tai-Tianqing Pharmaceutical Co. 有限公司, 诺华国际公司, 罗氏控股公司, 赛诺菲公司, Taiho Pharmaceutical Co. 有限公司. .

以数据为中心的报告重点关注市场趋势, 各细分市场的现状和前景. 全面覆盖不同细分市场, 该报告对于现有参与者来说是宝贵的资产, 新进入者和未来投资者.

为什么购买这份报告?
▹ Get a detailed picture of the China Oncology Drugs Market
▹ Identify segments/areas to invest in over the forecast period in the China Oncology Drugs Market
▹ 了解竞争环境, 市场的领先参与者
▹ Excel 格式的市场预估，方便跨场景分析.
▹ 三个月的策略咨询和研究支持.
▹ 为单用户许可证提供打印验证.